Eli Lilly (LLY) shares are extending gains on Wednesday after the FDA approved Foundayo — the company’s first once-daily oral GLP-1 for chronic weight management. As investors cheered the pivot to a more convenient, non-injectable alternative for obesity treatment, LLY broke above its 20-day moving average (MA), indicating the upward momentum may sustain in the near-term.
Despite the headline rally, however, Eli Lilly stock remains down over 10% versus the start of 2026.
Significance of Foundayo Approval for Eli Lilly Stock
For LLY shares, Foundayo approval is a game-changer because the oral pill addresses two major hurdles in the GLP-1 market: administration and supply.
Unlike current leaders (Zepbound and Wegovy), which require weekly injections, Foundayo is a small-molecule pill that can be taken any time of day without food or water restrictions.
This real-world convenience is expected to significantly expand the patient pool, particularly for those hesitant about needles, helping the firm capture a larger slice of the multi-billion-dollar GLP-1 market over time.
Moreover, as a chemical-based pill rather than a complex biologic, Foundayo is easier and cheaper to manufacture at scale, potentially easing the chronic supply shortages that have plagued Lilly’s injectable portfolio.
Where Options Data Suggests LLY Shares Are Headed
According to Barchart, options pricing signals continued momentum ahead. The put-to-call ratio on contracts expiring mid-June sits at 0.5x currently, indicating a strong bullish skew.
Meanwhile, the upper price on those contracts suggests roughly 14% upside in Eli Lilly shares to $1,099 within the next three months.
This concentration of call-buying at higher strikes implies institutional smart money is positioning for a breakout toward the company’s all-time high.
It's also worth mentioning that LLY also currently pays a dividend yield of 0.71%, which makes it all the more attractive as a long-term holding, at least for income-focused investors.
Eli Lilly Remains Buy-Rated Among Wall Street Firms
Wall Street analysts also seem to share options traders’ optimism on Eli Lilly, given the consensus rating on the pharmaceutical behemoth sits at “Strong Buy” currently.
The mean price target of about $1,238 suggests LLY stock could rally another 27% from here.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- This Dividend Stock Has Been Steady Amid the Iran War: Is It Still a Buy?
- Boeing Jumps on New Pentagon Deal. Should You Buy BA Stock Here?
- This Tech Stock May Be About to Short Circuit Near 52-Week Highs
- A Giant Meatpacking Strike Isn’t Enough to Dent the Bull Case for JBS Stock, According to Bank of America
